Biocon Biologics expands insulin access in Malaysia
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Star Health Insurance is modernising its claims ecosystem to be future-ready
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The transaction is expected to close in Q2 FY 2026
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Subscribe To Our Newsletter & Stay Updated